How to Use Palopegteriparatide
Complete guide to Palopegteriparatide dosing, administration, timing, and protocol recommendations.
Quick Overview
Palopegteriparatide is a long-acting prodrug of PTH(1-34), the active part of parathyroid hormone, built so that it releases steady hormone levels around the clock. Sold as Yorvipath by Ascendis Pharma, it was FDA approved in August 2024 as the first treatment specifically for hypoparathyroidism in adults, after a 2023 rejection over dose-delivery issues with the pen. With Natpara now gone, it is the main hormone replacement option for this condition, and the trial results are genuinely strong.
Dosing Guidelines
Common Dose
18 mcg once daily to start
Frequency
Once daily
Dose Range
6-30 mcg once daily
Note: Dose is individualized by serum calcium, checked 7-10 days after each change. Active vitamin D and calcium supplements are reduced on the start day per the label. Use one injection per dose; two injections to reach a dose increase the risk of unexpected calcium swings.
Administration Method
Subcutaneous injection once daily with a prefilled pen, using a single injection per dose
Best Time to Take
Same time each day
The released PTH has a half-life of about 60 hours, so levels stay steady and time of day matters less than consistency.
Protocol Duration
Long-term, as chronic hormone replacement
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (39%)
- •Dizziness, palpitations, orthostatic hypotension (28%)
- •Headache (21%)
- •Diarrhea
- •Back pain
Frequently Asked Questions
What is the recommended dose for Palopegteriparatide?
18 mcg once daily to start
How do you administer Palopegteriparatide?
Subcutaneous injection once daily with a prefilled pen, using a single injection per dose
When is the best time to take Palopegteriparatide?
Same time each day
How long should you use Palopegteriparatide?
Long-term, as chronic hormone replacement
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.